

reviewing our decision, we discovered that our analysis regarding the emission impacts of TOLAD MFA-10A was inadvertently based on the minimum treat rate of 25 mg/l, whereas Baker Hughes requested and provided data for TOLAD MFA-10A at a concentration of 42.7 mg/l.³ This correction notice therefore explains how our decision to approve TOLAD MFA-10A as an alternative corrosion inhibitor under the OCTAMIX waiver is still appropriate when using a concentration of 42.7 mg/l.

With regards to the question of the emission impacts of using TOLAD MFA-10A, its treat rate of 42.7 mg/l is the same as the treat rate of TOLAD MFA-10, the original corrosion inhibitor approved under the OCTAMIX waiver. The chemical composition and the treat rate of TOLAD MFA-10A at 42.7 mg/l, which is less than 0.01 mass percent by weight, is such that it qualifies as a fuel additive falling under the baseline gasoline fuel category⁴ under our fuel and fuel additive registration regulations. In addition, the chemical composition and treat rate of TOLAD MFA-10A at 42.7 mg/l is such that it meets our substantially similar definition.⁵ Given that TOLAD MFA-10A at a concentration of 42.7 mg/l is a fuel additive that is both substantially similar to fuel additives used in our certification program and a fuel additive falling under our baseline gasoline fuel category, one would not expect significant emission changes from the use of TOLAD MFA-10A compared to other fuel additives that fall under the baseline gasoline fuel category, which also includes TOLAD MFA-10, DMA-67 and TXCeel. Therefore, as long as the other conditions of the OCTAMIX waiver are met, which include applicable volatility specifications, gasoline phase separation specifications, and alcohol purity conditions, the Agency believes that the use of TOLAD MFA-10A in place of TOLAD MFA-10 will allow engines and vehicles to remain compliant with their emissions standards when using fuels made as approved under the original conditions granted for the OCTAMIX waiver.

The Agency therefore modifies condition (3) of the OCTAMIX waiver to read as follows:

(3) Any one of the following four corrosion inhibitors must be included:

(a) Petrolite's corrosion inhibitor formulation, TOLAD MFA-10, blended

in the final fuel at 42.7 milligrams/liter (mg/l); or

(b) DuPont's corrosion inhibitor formulation, DMA-67, blended in the final fuel at 31.4 mg/l; or

(c) Spirit of 21st Century LLC's corrosion inhibitor formulation, TXCeel, blended in the final fuel at 3.9 ml/gal (987.6 mg/l); or

(d) Baker Hughes's corrosion inhibitor formulation, TOLAD MFA-10A, blended in the final fuel at 42.7 mg/l.

III. Do any of the statutory and executive order reviews apply to this action?

This final decision corrects an error in our emissions impact analysis for TOLAD MFA-10A at 42.7 mg/l as well as corrects an error in the required treat rate of TOLAD MFA-10A at 42.7 mg/l for use with the OCTAMIX waiver. This final decision does not otherwise change the requirements in the June 14, 2012 decision notice. As a correction, this action is not subject to the statutory and Executive Order review requirements. For information about the statutory and Executive Order review requirements as they related to the final decision, see the Unit IV, in the **Federal Register** of June 14, 2012.⁶

Dated: October 25, 2012.

Lisa P. Jackson,

Administrator.

[FR Doc. 2012-26753 Filed 10-31-12; 8:45 am]

BILLING CODE 6560-50-P

OFFICE OF GOVERNMENT ETHICS

Agency Information Collection Activities; Emergency Clearance Submission for Expedited OMB Review; Proposed Information Collection; Comment Request for a Proposed OGE Form 201-A Ethics in Government Act Access Form

AGENCY: Office of Government Ethics (OGE).

ACTION: Emergency clearance notice and request for agency and public comments.

SUMMARY: The Office of Government Ethics (OGE) is submitting a request to the Office of Management and Budget (OMB) for an expedited emergency clearance for the proposed OGE Form 201-A Ethics in Government Act access form under the Paperwork Reduction Act of 1995 (44 U.S.C. chapter 35). OGE is requesting a temporary 180-day approval, effective November 9, 2012.

DATES: Written comments by the public and the agencies on this proposed information collection are invited and must be received on or before November 6, 2012.

ADDRESSES: Comments, identified by the title of the information collection activity, may be submitted to the Office of Information and Regulatory Affairs, Attn: Mr. Kevin Herms, OMB Desk Officer for the Office of Government Ethics:

FAX: 202-395-5167, Attn: Mr. Kevin Herms, OMB Desk Officer for the Office of Government Ethics; **Email:** kherms@omb.eop.gov.

Comments should also be submitted to the Office of Government Ethics, Attn: Mr. Paul Ledvina, Agency Clearance Officer:

FAX: 202-482-9237, Attn: Mr. Paul Ledvina, Agency Clearance Officer; **Email:** usoge@oge.gov.

FOR FURTHER INFORMATION CONTACT: Paul Ledvina at the Office of Government Ethics; telephone: 202-482-9247; TTY: 800-877-8339; FAX: 202-482-9237; Email: paul.ledvina@oge.gov.

SUPPLEMENTARY INFORMATION:

Title: Request to Inspect or Receive Electronic Copies of Executive Branch Personnel Public Financial Disclosure Reports, including Periodic Transaction Reports, filed on or after January 1, 2012.

Agency Form Number: OGE Form 201-A.

OMB Control Number: 3209-0002.

Type of Information Collection: New collection.

Type of Review Request: Emergency expedited review for temporary 180-day approval.

Respondents: Individuals requesting electronic access to executive branch public financial disclosure reports, including periodic transaction reports, filed on or after January 1, 2012, and posted to the Internet in accordance with section 11(a) of Public Law 112-105, 126 Stat. 291 (2012).

Estimated Annual Number of Respondents: 1,246.

Estimated Time per Response: 5 minutes.

Estimated Total Annual Burden: 104 hours.

Abstract: The proposed OGE Form 201-A would collect certain information from, and provide certain information to, persons who seek access to electronic copies of public financial disclosure reports, including periodic transaction reports, filed on or after January 1, 2012, and posted on the Internet in accordance with section 11(a) of Public Law 112-105, 126 Stat. 291 (2012). Specifically, the OGE Form

³ NACE Standard TM-01-72.

⁴ See 40 CFR 79.56(e)(3)(i).

⁵ For our most recent substantially similar gasoline interpretive rule, please see: <http://www.epa.gov/fedrgst/EPA-AIR/2008/April/Day-25/a8944.pdf>.

⁶ 77 FR 35679.

201–A would collect the following information from any requesting person seeking access to such reports: the person's name and the person's city, state and country of residence. OGE has the authority under section 402(b)(1) of the Ethics in Government Act to require executive branch agencies to collect such information before requested reports are made available to the requester. See 5 U.S.C. appendix section 402(b)(1), and 5 CFR 2634.603(c) and (f). The proposed OGE Form 201–A would be used solely in an automated, Web-based application. No statistics of previous usage are available upon which to base an estimated annual number of respondents because this proposed information collection is a new form. OGE's annual estimate is based upon the number of requests OGE has received for access to public financial disclosure reports of presidential appointees confirmed by the Senate through OGE's Web site via the new automated Office of Government Ethics Form 201 access request form. OGE received 408 requests during the six-month period from the initial launch of the new automated Office of Government Ethics Form 201 in March through August 2012. OGE then added the total number of access requests received by all other executive branch agencies, for a similar length of time, during the most recent period (calendar year 2011) for which executive branchwide statistics are available, which was 215 such requests. The total number of access request forms received by all executive branch agencies, including OGE, in a 6-month period totaled 623. This number was multiplied by two to provide the estimate of 1,246 annual respondents.

Request for Comments: Agency and public comment is invited specifically on the need for, and practical utility of, this information collection; the accuracy of OGE's burden estimate; the enhancement of quality, utility and clarity of the information collected; and the minimization of burden (including the use of information technology). Comments received in response to this notice will be summarized for, and may be included with, OGE's subsequent request to OMB for a 3-year paperwork approval. The comments will also become a matter of public record.

Approved: October 17, 2012.

Don W. Fox,

Acting Director, Office of Government Ethics.

[FR Doc. 2012–26101 Filed 10–31–12; 8:45 am]

BILLING CODE 6345–03–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; PAR–11–350 Research Using Biosamples from Selected Type 1 Diabetes Clinical Studies (DP3).

Date: December 4, 2012.

Time: 1:30 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Ann A. Jerkins, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 759, 6707 Democracy Boulevard, Bethesda, MD 20892–5452, 301–594–2242, jerkinsa@nidk.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: October 26, 2012.

David Clary,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2012–26829 Filed 10–31–12; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as

amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Child Health and Human Development Special Emphasis Panel; Environmental and Biological Variation and Language Growth.

Date: November 27, 2012.

Time: 1:00 p.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6100 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call).

Contact Person: Marita R. Hopmann, Ph.D., Scientific Review Officer, Division of Scientific Review, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, 6100 Executive Blvd., Room 5B01, Bethesda, MD 20892, 301–435–6911, hoppmann@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS)

Dated: October 26, 2012.

Michelle Trout,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2012–26830 Filed 10–31–12; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning